Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in BCRX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 22.7M | $215.6M | +7.2% | 10.792% | 0.00% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 15.8M | $150.7M | 0.0% | 7.541% | 1.60% |
| 3 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 15.0M | $143.2M | +4.9% | 7.165% | 1.69% |
| 4 | STATE STREET CORP | 12.2M | $116.2M | +10.3% | 5.816% | 0.00% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11.2M | $107.0M | β | 5.357% | 0.01% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 11.1M | $106.0M | β | 5.305% | 0.00% |
| 7 | TCG Crossover Management, LLC | 11.0M | $104.9M | β | 5.251% | 3.00% |
| 8 | JANUS HENDERSON GROUP PLC | 8.9M | $84.9M | +20.3% | 4.244% | 0.04% |
| 9 | PERCEPTIVE ADVISORS LLC | 7.4M | $70.8M | +135.1% | 3.542% | 1.40% |
| 10 | Vestal Point Capital, LP | 7.0M | $66.9M | +212.2% | 3.347% | 1.87% |
| 11 | TWO SIGMA INVESTMENTS, LP | 6.4M | $60.9M | +41.6% | 3.046% | 0.05% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 5.8M | $55.1M | +14.4% | 2.755% | 0.00% |
| 13 | Kynam Capital Management, LP | 5.7M | $54.1M | -39.4% | 2.706% | 3.38% |
| 14 | BANK OF AMERICA CORP /DE/ | 5.1M | $48.5M | +231.6% | 2.426% | 0.00% |
| 15 | abrdn plc | 5.0M | $48.0M | +451.7% | 2.401% | 0.08% |
| 16 | UBS Group AG | 4.9M | $47.1M | -6.2% | 2.356% | 0.01% |
| 17 | Frazier Life Sciences Management, L.P. | 4.0M | $38.2M | β | 1.910% | 0.98% |
| 18 | Royalty Pharma Sub-Manager, LLC | 3.8M | $36.6M | β | 1.832% | 10.64% |
| 19 | Nuveen, LLC | 3.8M | $36.4M | +5.7% | 1.820% | 0.01% |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 3.2M | $30.0M | +137.3% | 1.502% | 0.00% |
| 21 | Eversept Partners, LP | 3.0M | $28.9M | +1.6% | 1.448% | 1.89% |
| 22 | RFG Advisory, LLC | 2.9M | $27.3M | β | 1.368% | 0.50% |
| 23 | Fisher Asset Management, LLC | 2.7M | $26.0M | +10.8% | 1.302% | 0.01% |
| 24 | DIMENSIONAL FUND ADVISORS LP | 2.7M | $25.6M | +119.0% | 1.282% | 0.01% |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.4M | $22.4M | +17.2% | 1.120% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in BCRX β a direct measure of their conviction.
Filings activity in BCRX during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new BCRX position in Q1 2026
Institutions that fully closed their BCRX position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 292 | +9.0% | 125.37% | +37.64 pp | $2.29B | +43% |
| Q4 2025 | 268 | 3.6% | 87.73% | +8.58 pp | $1.60B | +11% |
| Q3 2025 | 278 | 3.1% | 79.15% | 12.75 pp | $1.45B | 14% |
| Q2 2025 | 287 | +7.1% | 91.90% | +23.01 pp | $1.68B | +33% |
| Q1 2025 | 268 | +7.2% | 68.89% | +2.16 pp | $1.26B | +3.2% |
| Q4 2024 | 250 | 0.4% | 66.73% | 1.18 pp | $1.22B | 1.7% |
| Q3 2024 | 251 | +8.2% | 67.91% | +11.58 pp | $1.24B | +21% |
| Q2 2024 | 232 | β | 56.33% | β | $1.03B | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying BCRX stock.
Based on Q1 2026 13F filings, institutional ownership of BioCryst Pharmaceuticals, Inc. stands at 125.4%, held across 292 reporting institutions.
BlackRock, Inc. is the largest reported institutional holder of BCRX, with approximately 22,650,988 shares worth $0.22B as of Q1 2026.
Yes β 3 widely-followed marquee investors appear among the top 25 institutional holders of BCRX, including TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Fisher Asset Management, LLC.
Our composite Smart Money Score for BCRX is 74 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
75 institutions opened new positions in BCRX during Q1 2026, while 51 fully exited. 171 added to existing positions and 45 trimmed.
BCRX institutional ownership rose by 37.64 percentage points quarter-over-quarter, with a net change of +24 holders.
The top 10 institutions account for 50.9% of all reported 13F value in BCRX, and the top 25 account for 76.5%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
BioCryst Pharmaceuticals, Inc. (BCRX) Institutional Ownership